SynthesisMycopathologia2025
A Systematic Review on the Emerging Fungal Pathogen Neoscytalidium Causing Infections Worldwide.
Synthesis in Mycopathologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- From trauma to brain:IDCases · 2026Article
- Case Report: Destructive deep infection of the foot caused byFrontiers in immunology · 2026Article
- Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Article
- Phylogenetic assessment and taxonomic revision ofIMA fungus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scytalidiosis is a dermatomycosis caused by fungi of the genus Neoscytalidium. An increase in the number of cases at the global level has been reported. In the present study, the clinical characteristics of patients diagnosed with scytalidiosis were analyzed through a systematic review of cases reported in the literature. An advanced search was conducted through four databases: MEDLINE/PubMed, SCOPUS, Embase, and SciELO using the terms "Neoscytalidium" or "Scytalidium". A total of 155 reports with 5,097 cases were analyzed of which 30.12% were women and 27.31% were men. A total of 37 countries reported cases of scytalidiosis. The USA, Thailand, France, Brazil, Colombia, and the UK had the highest number of cases. The most prevalent species were N. dimidiatum (38.96%) and N. hyalinum (7.47%). One case of N. oculus sp. nov. and seven instances of N. novaehollandiae were also reported. Regarding the clinical presentation, 68.30% of patients had onychomycosis, 5.93% had skin infections, and 24.16% presented both types of infections. Other less frequent presentations (1.61%), including keratitis/endophthalmitis, CNS infection, invasive or disseminated infection, sinusitis/rhinosinusitis, mycetoma, endocarditis, and dyskeratosis were also reported. This review shows that the epidemiology of scytalidiosis is changing, other regions that had not been considered endemic are now reporting the highest number of cases. Neoscytalidium spp. should be considered an important emerging pathogen and the main non-dermatophyte fungus causing onychomycosis and skin infections after dermatophytes. Likewise, other clinical presentations caused by this fungal pathogen should not be underestimated, especially in patients with some immunocompromise or underlying disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.